Report: Medtech R&D looking to diversification, non-traditional partners to handle hurdles in innovation

德勤、 AdvMed 发布调查报告:非传统合作伙伴成医疗科技公司新需求

2018-12-05 07:49:40 mass

本文共747个字,阅读需2分钟

Portfolio diversification, improving time to market and the use of real-world evidence are top priorities amongst R&D leaders at medtech companies, according to data from a new survey. Investigators in the survey, performed by Deloitte and AdvMed, were looking to explore challenges R&D leaders face in medtech and how they are responding to shifts throughout the industry. The report includes responses from research and development leaders at 22 mid-sized and large medtech companies, surveyed between April and August this year. The survey included questions on R&D investments, sources of innovation, regulatory impacts and other priorities and challenges, Deloitte wrote in the report. Of the executives surveyed, 86% said that portfolio diversification tops their priorities for handling a “need to drive innovation, improve margins and reduce cost.” A total of 82% reported accelerating time to market as a priority, while 77% said that leveraging real-world evidence in product development was a top concern. Only 64% and 55% of respondents indicated that developing digitally enabled solutions and software and improving product quality or reducing risk were priorities, respectively. Medtech may be looking more to nontraditional partners, including tech and healthcare companies, to drive their innovation, Deloitte reports. Eighty-two percent of companies surveyed said they plan to seek such collaborations over the coming years, almost double the current 42%. Increasing complexity amongst global regulatory bodies was identified by 95% of respondents as a top challenge for R&D leaders over the next three to five years, while 64% of respondents said that regulatory complexity was affecting new product development decisions. New payment models are contributing significantly to shifts in R&D focus according to the report. Sixty-eight percent of respondents said that they changed their focus on innovation due to “payment model and care delivery reforms.” While 100% of those surveyed said that they were investing in device connectivity, 77% said that data integration in new technology was a “key challenge,” according to the report. In response to the challenges, a total of 73% of those surveyed said they are adopting hybrid operating models that combine centralized and decentralized resources, according to Deloitte.
一项最新调查的数据显示,投资组合多样化、缩短上市时间以及使用真实证据是医疗科技公司研发主管们的首要任务。 德勤( Deloitte )和 AdvMed 公司( AdvMed )开展的调查的调查人员,正在探索研发领导者在医疗科技领域面临的挑战,以及他们如何应对整个行业的转变。 这份报告包括今年4月至8月接受调查的22家大中型医疗科技公司的研发负责人的回应。德勤在报告中写道,调查内容包括研发投资、创新来源、监管影响以及其他优先事项和挑战。 在接受调查的高管中,86%的人表示,投资组合多元化是他们处理“需要推动创新、提高利润率和降低成本”的首要任务。有82%的受访者表示,优先考虑加快上市时间,77%的受访者表示,在产品开发中充分利用现实世界的证据是最令人担心的问题。 只有64%和55%的受访者表示,开发数字化解决方案和软件以及提高产品质量或降低风险分别是优先事项。 德勤( Deloitte )报告称, Medtech 可能会更多地寻求非传统合作伙伴,包括科技和医疗公司,以推动创新。82%接受调查的公司表示,他们计划在未来几年寻求这种合作,几乎是目前42%的两倍。 95%的受访者认为,在未来三到五年内,全球监管机构的复杂性不断增加是研发领导者面临的最大挑战,而64%的受访者表示,监管复杂性正在影响新产品开发决策。 报告称,新的支付模式对研发重点的转变做出了重大贡献。68%的受访者表示,由于“支付模式和护理交付改革”,他们改变了对创新的关注。 报告称,尽管100%的受访者表示,他们正在投资于设备连接,77%的受访者表示,新技术的数据集成是一个“关键挑战”。 德勤( Deloitte )表示,为应对这些挑战,总共有73%的受访者表示,他们正在采用集中和分散资源相结合的混合运营模式。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文